Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SeaStar Medical Holding (ICU) Gains from Sales and Divestitures (2023 - 2025)

SeaStar Medical Holding (ICU) has disclosed Gains from Sales and Divestitures for 3 consecutive years, with $76384.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gains from Sales and Divestitures rose 731.8% year-over-year to $76384.0, compared with a TTM value of $76384.0 through Sep 2025, up 731.8%, and an annual FY2024 reading of $9183.0, changed N/A over the prior year.
  • Gains from Sales and Divestitures was $76384.0 for Q3 2025 at SeaStar Medical Holding, up from $747.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $186244.0 in Q3 2023 and bottomed at $747.0 in Q2 2025.
  • Average Gains from Sales and Divestitures over 3 years is $52382.9, with a median of $9194.0 recorded in 2024.
  • The sharpest move saw Gains from Sales and Divestitures crashed 95.07% in 2024, then soared 731.8% in 2025.
  • Year by year, Gains from Sales and Divestitures stood at $186244.0 in 2023, then plummeted by 95.07% to $9183.0 in 2024, then skyrocketed by 731.8% to $76384.0 in 2025.
  • Business Quant data shows Gains from Sales and Divestitures for ICU at $76384.0 in Q3 2025, $747.0 in Q2 2025, and $7417.0 in Q1 2025.